Integrated Wealth Concepts LLC grew its stake in shares of GSK plc (NYSE:GSK – Free Report) by 18.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,270 shares of the pharmaceutical company’s stock after purchasing an additional 3,519 shares during the period. Integrated Wealth Concepts LLC’s holdings in GSK were worth $792,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the stock. Glassman Wealth Services boosted its position in shares of GSK by 504.6% in the 4th quarter. Glassman Wealth Services now owns 925 shares of the pharmaceutical company’s stock worth $33,000 after buying an additional 772 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of GSK by 61.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after buying an additional 368 shares in the last quarter. Concord Wealth Partners purchased a new stake in shares of GSK in the 4th quarter worth about $45,000. Hazlett Burt & Watson Inc. boosted its position in shares of GSK by 98.5% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 1,310 shares of the pharmaceutical company’s stock worth $46,000 after buying an additional 650 shares in the last quarter. Finally, Valley National Advisers Inc. boosted its position in shares of GSK by 27.8% in the 1st quarter. Valley National Advisers Inc. now owns 1,328 shares of the pharmaceutical company’s stock worth $49,000 after buying an additional 289 shares in the last quarter. 13.29% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. StockNews.com assumed coverage on shares of GSK in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. HSBC initiated coverage on shares of GSK in a research note on Friday, July 14th. They issued a “reduce” rating for the company. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $1,527.50.
GSK Trading Down 1.8 %
GSK Cuts Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.3613 per share. This represents a $1.45 dividend on an annualized basis and a dividend yield of 4.14%. The ex-dividend date is Thursday, August 17th. GSK’s dividend payout ratio is currently 16.10%.
GSK Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading
- Five stocks we like better than GSK
- Insider Buying Explained: What Investors Need to Know
- JetBlue Airlines May Have Entered A Buy Zone, Check This First
- Investing in Travel Stocks Benefits
- Investors Are Staying Bullish On Marriot International
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Do Caterpillar’s Results Hint at a Looming Infrastructure Bubble?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
